Argenica Therapeutics Ltd has released a press release.
ARG-007 Phase 2 Clinical Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- ARG-007 Protects Brain Cells in Moderate TBI Model
- Argenica Successfully Completes $4.0m Placement
- Final Phase1 Clinical Trial Report
- Latest Preclinical HIE Study Results
- Significant Non-Dilutive Funding For Preclinical HIE Studies
Later from Argenica Therapeutics
- Investor Presentation
- ARG-007 Prevents Uptake & Aggregation of Key Protein
- Response to ASX Aware Query
- Appendix 4E & Annual Report 30 June 2023
- Positive FDA Feedback Following Pre-Ind Meeting
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics